NCT04582968: Pyrotinib Combined With Brain Radiotherapy in Breast Cancer Patients With Brain Metastases

NCT04582968
Breast Cancer Type: HER2+
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: 

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have intracranial metastases with a maximum diameter less than 3cm measured by enhanced brain MRI
Exclusions: Patients with leptomeningeal disease; Patients with prior use of pyrotinib combined with capecitabine
https://ClinicalTrials.gov/show/NCT04582968

Comments are closed.

Up ↑